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Background: HIV clonal genotypic analysis (CG) was used to investigate whether a more sensitive analysis
method would detect additional low-abundance mutations compared with population genotyping (PG) in anti-
retroviral-naive patients who experienced virological failure (VF) during treatment with abacavir/lamivudine/
zidovudine and tenofovir.
Methods: HIV was analysed by PG and CG (771 baseline and 657 VF clones) from subjects with VF (conﬁrmed
HIV RNA  400 copies/mL at 24–48 weeks).
Results: Fourteen of 123 subjects (11%) met VF criteria; their median baseline HIV RNA was 5.4 log10 copies/mL,
and 4.0 log10 copies/mL at VF. By baseline PG, 2/14 had HIV-1 with nucleoside reverse transcriptase inhibitor
(NRTI) or non-NRTI mutations. By baseline CG, 9/14 had HIV-1 with NNRTI and/or NRTI mutations; 7/9 had study
drug-associated mutations. By PG at VF, 10/14 had selected for resistance mutations [2, K65R; 1, M184V; and 7,
thymidine analogue mutations (TAMs)+M184V]. By CG at VF, for subjects with TAMs, T215F was more commonly
detected (5/14samples) than T215Y(2/14). Foronesubject whoselected K65R at VF, bothK65R-containing clones
andTAM-containingclones(bothT215AandT215F)wereobservedindependentlybutnotconjunctivelyinthesame
clone in a post-VF sample.
Conclusions: The majority of subjects with VF had major and minor mutations detected at VF; CG detected
additional low-abundance variants at baseline and VF that could have inﬂuenced mutation selection pathways.
Both PG and CG data suggest TAMs, not K65R selection, are the preferred resistance route, biased towards 215F
selection. No HIV clone contained both K65R and T215F/Y mutations, suggesting in vivo antagonism between
the two mutations. The once-daily zidovudine usage and high baseline viraemia may also have contributed to
rapid selection of HIV with multiple mutations in VFs.
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Introduction
When treating HIV-infected patients, HIV genotyping is com-
monly utilized as a diagnostic tool if the patient does not
respond to therapy or if the patient experiences viral rebound.
It has been previously observed that population genotyping
(PG) can underestimate mutations, since minority quasi-species
may not be detected.
1,2 Certain drug resistance mutations in
the reverse transcriptase have also been shown in vitro to be
mutually antagonistic, e.g. the mutation K65R and the thymidine
analogue mutations (TAMs; i.e. M41L, D67N, K70R, L210W,
T215F/Y and K219Q/E), such that they are rarely detected
in vivo in the same sample by population sequencing.
3,4 K65R
can be selected in vivo by the drugs tenofovir and abacavir but
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307its frequency appears to be highly dependent on the other drugs
used within the regimen.
5,6 In vitro, it reduces susceptibility to all
marketed nucleoside reverse transcriptase inhibitors (NRTIs)
except zidovudine.
7,8 In studies where triple regimens of tenofo-
vir, abacavir and lamivudine or tenofovir, didanosine and lamivu-
dine were given to antiretroviral-naive subjects, the majority of
subjects experiencing virological failure (VF) selected for M184V
and K65R.
5,9–11 In contrast, TAMs are typically selected in vivo
by zidovudine and stavudine. TAMs confer reduced susceptibility
to both drugs, and certain combinations of TAMs can also confer
broad resistance to the NRTI class, including tenofovir.
12–15
COL40263 was a pilot 48 week, open-label, multicentre study
in antiretroviral-naive patients evaluating the efﬁcacy and safety
of a once-daily regimen including a ﬁxed-dose combination of
abacavir/lamivudine/zidovudine (300/150/300 mg/tablet, two
tablets taken once daily) and tenofovir (300 mg, one tablet/
day).
16 Prior HIV analysis by PG and by population phenotypic
analysis of samples from COL40263 subjects with VF had
demonstrated that selection of resistance via the TAM pathway
was preferred to selection via the K65R pathway, suggesting
that inclusion of zidovudine in the tenofovir/abacavir/lamivudine
regimen could modulate selection to favour selection of TAMs.
17
Here, samples from the subjects who experienced VF in
COL40263 were evaluated using clonal genotypic analysis (CG).
Using this more sensitive methodology we hoped to determine
whether there was additional resistance to study drugs unde-
tected by PG at baseline or at the time of VF that could have
impacted the selection pathway, and whether the mutational
antagonism between K65R and TAMs, as suggested by the
in vitro data, would result in detection of clonal variants in these
VF samples that would contain either K65R or TAMs, but not both.
Methods
Study design
COL40263 was a 48 week non-randomized, single-arm, open-label
observational pilot study conducted at 11 centres in the USA. All subjects
received abacavir/lamivudine/zidovudine (300/150/300 mg/tablet, two
tablets taken once daily) plus 300 mg of tenofovir once daily (one tablet),
and the study was designed to assess the impact of this regimen in
subjects with higher HIV RNA at entry; therefore, only subjects with HIV
RNA  30000 copies/mL at study screening were enrolled. All subjects
were  18 and  65 years of age with documented HIV-1 infection and
were antiretroviral therapy (ART) naive.
The multicentre COL40263 study was approved by either a central or a
local Institutional Review Board. Subjects provided written informed
consent to participate in the study and for sample analysis. VF was
deﬁned as conﬁrmed HIV-1 RNA  400 copies/mL at  24 weeks. All
plasma HIV-1 RNA concentrations were conﬁrmed by a second measure-
ment 2–4 weeks after the ﬁrst measurement.
Genotypic analysis
HIV was isolated from plasma from the 14 patients experiencing VF.
Samples were analysed by PG, and these results were compared with
those obtained from samples collected at baseline (VIRCO, Mechelen,
Belgium). CG was performed for the baseline and VF timepoints at Glaxo-
SmithKlineusingaliquotsofthesameplasmasamples.Atotalof771base-
line clonal sequences and 657 VF sequences were analysed. The clonal
genotyping methodologies were as follows: viral RNA was extracted from
1 mLofpatientplasmausingamagneticsilicaparticlemethod(miniMagTM,
bioMe ´rieux, Durham, NC, USA). RT–PCR ampliﬁcation of the viral pol gene
and conﬁrmatory PG were performed using the TruGeneTM HIV-1 Genotyp-
ing Kit and OpenGeneTM System (Siemens Healthcare Diagnostics Inc.,
Deerﬁeld, IL, USA). Amplicons were directly cloned from the same RT–PCR
using the Zero-Blunt
w TOPO PCR cloning system (Invitrogen, Carlsbad, CA,
USA). Individual colonies grown on selective medium were separately iso-
lated, followed by PCR ampliﬁcation with HIV-1-speciﬁc primers. The
colony PCR product was puriﬁed and sequenced with HIV-1-speciﬁc
primers using an ABI 377 automated sequencer and Prism FS technology
(PEBiosystems,FosterCity,CA,USA).NRTIandnon-NRTI(NNRTI)resistance
mutations were analysed as per the current IAS-USA Drug Resistance
Mutations group guidelines (http://www.iasusa.org),
18 except that NNRTI
mutations solely associated with etravirine resistance were not included,
and the non-IAS-USA-deﬁned mutations D67G and S68 (any) and T215
reversion mutations were included in the analysis. Unusual amino acid
changes detected at resistance sites are also shown for the CG data.
Results
One hundred and twenty-three subjects enrolled in COL40263.
The full safety and efﬁcacy results from the COL40263 study
have been published.
16 Subjects who met the criteria for VF in
COL40263 (n¼14) had a higher median baseline HIV RNA of
5.44 log10 copies/mL than the rest of the study population
(n¼109, HIV RNA 5.04 log10 copies/mL). Twelve of the 14 sub-
jects with VF had baseline HIV RNA  100000 copies/mL com-
pared with 60/109 of the non-failure population. The 14
subjects with VF also had a much lower median baseline CD4þ
(124 cells/mm
3) than the rest of the population (225 cells/
mm
3), were slightly younger (median 36.5 versus 38 years) and
were more likely to be black (79% versus 36%) than white
(21% versus 50%) or Hispanic (0% versus 15%).
Baseline HIV genotypic mutation proﬁles in the 14
subjects with VF
The mutations detected at baseline and at the time of VF by PG
as compared with the mutations and mutational linkages
detected by CG are shown in Table 1. By PG, 2/14 subjects had
NNRTI or NRTI mutations at baseline. Of the 12 subjects with
wild-type HIV at baseline by PG (without NRTI or NNRTI
mutations), CG identiﬁed additional resistance mutations that
were not detected by PG in 7/12 samples. Mutations detected
by CG at baseline that could have impacted response to one or
more study drugs included mutations at T215, K70E, D67G,
M184V and the multi-NRTI Q151M-associated mutations A62V
and F77L. The Y188L NNRTI mutation and unusual amino acid
mutations at NNRTI resistance sites that might reﬂect reversion
of NNRTI mutations (e.g. K103R, Y181H and G190E) from
archived drug-resistant virus were also detected in some base-
line samples by CG. In total, CG detected NNRTI or NRTI
mutations, or both, at baseline in 9/14 VF subjects. Seven of
these 14 subjects had baseline mutations with the potential to
impact one or more study drugs.
HIV genotypic mutation proﬁles in the 14 VF subjects
at VF
Seven of the VF subjects at baseline had resistance mutation-
containing low-abundance viral species (including one of more
of the following: A62V, F77L, K70E, T215A, T215S, D67G,
Ross et al.
308Table 1. Comparison of HIV resistance-associated mutations detected when analysed by conventional sequencing techniques (population genotype) and when using the more
sensitive method of clonal analysis to analyse HIV-1 isolated at the baseline (pre-therapy) visit and virological failure (VF) for the 14 subjects who met VF criteria in COL40263
Subject
Pre-therapy baseline sample VF sample
HIV RNA
log10 copies/mL population genotype clonal genotype
a timepoint
HIV RNA
log10 copies/mL population genotype clonal genotype
a
1 5.25 WT WT (17/17) week 32 2.77 K65K/R K65R (16/61)
K65RþS68N (20/61)
K65RþY115F (25/61)
3.52 Additional (post-VF) clonal analysis
 at week 36
WT (6/23)
K65RþS68N (10/23)
K65R (2/23)
K65RþY115F (3/23)
D67NþL210WþT215F (1/23)
T215A (1/23)
2 5.3 WT WT (58/105) week 48 2.87 K65RþS68N/SþY115F/Yþ
V118I
K65RþY115F (6/48)
M184V (1/105) K65RþS68N (16/48)
K70E (1/105) K65RþS68NþY115F (26/48)
V118I (45/105)
3 5.85 WT WT (33/33) week 32 3.36 D67NþK70RþM184V WT (7/46)
V118I (8/46)
D67NþK70RþM184V (18/46)
D67NþK70RþM184VþK219E
(10/46)
D67NþK70RþM184VþK219Q
(3/46)
4 6.11 WT WT (77/77) week 32 4.55 T215Y WT (7/74)
T215Y (63/74)
T215YþM41L (4/74)
5 5.34 K103K/Nþ
Y188F/H/L/Y
WT (8/30) week 32 4.23 M41LþD67NþK70Rþ
M184VþT215FþK219E
WT (11/50)
Y188L (7/30) M41LþD67NþK70Rþ
Y188LþM184VþT215Fþ
K219E (34/50)
K103N (13/30)
M41LþD67NþK70Rþ
Y188LþM184VþT215Lþ
K219E (1/50)
K103NþT215A
(2/30)
Y188L (3/50)
M41LþD67NþK70RþY188L (1/50)
6 5.18 WT WT (127/128) week 24 4.15 WT WT (31/31)
T215S (1/128)
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Subject
Pre-therapy baseline sample VF sample
HIV RNA
log10 copies/mL population genotype clonal genotype
a timepoint
HIV RNA
log10 copies/mL population genotype clonal genotype
a
7 5.72 WT WT (53/53) week 32 3.59 M184V M184V (36/62)
M184VþD67G (1/62)
D67NþT215F (21/62)
M184VþT215S (1/62)
D67NþK70RþT215Y (1/62)
D67NþS68GþT215Y (1/62)
K65RþS68NþY115FþV118I
(1/62)
8 4.4 WT WT (44/46) week 32 2.68 WT WT (35/36)
K219Q (2/46) L210W (1/36)
9 5.84 T215T/A WT (47/56) week 28 5.08 D67NþL210L/WþT215F D67NþT215F (64/92)
D67G (1/56) D67NþK70RþT215F (13/92)
T215A (8/56) D67NþM184VþT215F (2/92)
D67NþL210WþT215F (13/92)
10 5.30 WT WT (68/73) week 24 3.54 D67NþK70K/RþT215F M184VþT215F (1/64)
M41I (1/73) D67NþT215F (36/64)
K103R (1/73) D67NþT215Y (1/64)
Y181H (1/73) M41LþD67NþT215F (6/64)
M184V (1/73) M41VþD67NþT215F (1/64)
G190E (1/73) M41VþD67NþG190EþT215F
(1/64)
A62TþD67NþT215F (1/64)
D67NþK70RþT215F (12/64)
D67NþK70RþM184V (1/64)
D67NþG190EþT215F (1/64)
D67NþK70TþT215F (1/64)
D67NþT215FþK219T (2/64)
11 5.11 WT WT (13/13) week 40 2.8 D67NþK70RþM184V WT (10/16)
D67NþK70Rþ184V (1/16)
D67NþM184V (1/16)
D67NþK70RþM184VþK219E
(4/16)
12 4.72 WT WT (49/58) week 24 4.2 WT WT (56/57)
Y188L (9/58) Y188L (1/57)
13 5.54 WT WT (66/67) week 40 4.6 WT WT (30/31)
F77L (1/67) M184I (1/31)
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0M184Vor K219Q) with the potential to impact response to one or
more study drugs. At failure, virus from ﬁve of these seven sub-
jects contained TAMs with or without M184V (Subjects 5, 8, 9, 10
and 14) or K65R (Subject 2). The only subject with TAMs detected
at baseline who did not have detectable TAMs at failure was
Subject 6, who had only a very low incidence of T215S (1/128
clones) at baseline. Certain TAM reversion mutations detected
at baseline by CG were no longer detected at the time of VF
and may have been outcompeted by other mutations. For
example, Subjects 5 and 9 had HIV with T215A reversion
mutations at baseline, but not at VF (where T215F was detected
in virus from both subjects). Phylogenetic analysis of the clonal
sequences from Subject 5 (Figure 1) illustrates the genetic diver-
sity at baseline and the divergence into three distinct groups of
variants at VF. At baseline, Subject 5 had viral clones containing
K103N with or without T215A, or with Y188L resistance
mutations, while at VF clones with one or more of the following
mutations: M41L, D67N, K70R, M184V, Y188L, T215F or L, and
K219E were detected, but K103N and T215A were not.
Only four subjects (Subjects 6, 8, 12 and 13) had wild-type
HIV as measured by PG at both baseline and VF. However,
when analysed by CG, low-abundance viral species containing
resistance mutations were detected in three of these four sub-
jects at VF (L210W for Subject 8, Y188L for Subject 12 and
M184I for Subject 13). The L210W and M184I mutations were
treatment emergent for Subjects 8 and 13, respectively, while
the NNRTI mutation Y188L that was observed by CG at VF for
Subject 12 had also been detected at baseline by CG (but not
by PG). Interestingly, although Subject 8 had low-abundance
viral species containing the L210W mutation by VF, a different
TAM (K219Q) had been detected at baseline by CG.
By PG at VF, virus from seven subjects had selected for
TAMs or for TAMs plus an M184V mutation. In 6/7 of these
subjects, CG revealed additional TAMs or M184V that were
not detected by PG. The T215F variant was much more com-
monly detected than T215Y. In the remaining subject (Subject
5), 5/6 TAMs plus M184V were already detected by PG at VF.
Although it is common for M184V mutations to be selected
along with TAMs in subjects failing on regimens containing
zidovudine and lamivudine, in this study a relatively small
number of subjects had virus with M184V at VF (3/14 by PG,
7/14 by CG). Interestingly, when utilizing the more sensitive
method of clonal analysis, at the last study visit examined
by CG four of the VF subjects had virus with TAMs but no
viral clones that also contained the M184V mutation (Subjects
1, 4, 8 and 14).
Two subjects with baseline wild-type virus by PG selected for
the K65R mutation at VF. Viruses from both of these subjects
were clade B. For Subject 1, both the VF and a timepoint
4 weeks after VF were analysed by CG. At baseline by both PG
and clonal analysis, only wild-type HIV-1 was detected for
Subject 1. At VF, Subject 1 population sequencing revealed only
K65K/R, and only clones with the K65R mutation were observed
at the ﬁrst timepoint (with or without Y115F and S68 mutations),
but at the later timepoint TAM-containing clones (one clone with
D67NþL210WþT215F and another clone with T215A) were also
detected in addition to K65R-containing clones. For Subject 2,
K70E was detected by CG at baseline, followed by selection of
K65R at failure. Interestingly, Subject 2 also had viral clones
with M184Valone at baseline; however, M184V was not detected
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JACat failure. The phylogenetic proﬁle from the clonal sequences for
Subject 2 is shown in Figure 2. The tight clustering of the
non-wild-type failure sequences suggests that they arose from
a small segment of the baseline population, with replication
occurring by only a few mutational pathways. This genetic bot-
tlenecking could have resulted from the observed incomplete
suppression of replication in the presence of drug for those
viruses that had already selected for study drug resistance-
associated mutations.
Discussion
The resistance pattern for the 14 subjects with VF in COL40263
differs signiﬁcantly from that previously reported for tenofovir-
containingtriplenucleosideregimens.
5,9–11Virusfromthemajority
of subjects with VF in COL40263 selected for TAMs at VF. The more
sensitive technique of CG conﬁrmed the PG ﬁndings that virus from
the majority of VF selected for TAMs at failure, and detected the
presence of one or more additional TAMs at low incidences.
Figure 1. Phylogenetic analysis of plasma HIV variants isolated from a representative subject (Subject 5) whose baseline HIV-1 RNA was
5.34 log10 copies/mL and whose baseline (pre-therapy) population genotype resistance mutations included K103K/NþY188F/H/L/Y and who at failure
had an HIV-1 RNA of 4.23 log10 copies/mL and a population genotype of M41LþD67NþK70RþM184VþT215FþK219E. Clonal analysis detected
distinct viral species, and some of these clonal variants contained different mutational patterns at baseline and at VF from those observed by
population sequencing. Phylogenetic trees were constructed by using the neighbour-joining method and out-grouped with HXB2RT (HXB2 reverse
transcriptase reference sequence). The scale indicates the relative phylogenetic distance. WT, wild-type.
Ross et al.
312Figure 2. Phylogenetic analysis of plasma HIV variants isolated from a representative subject (Subject 2) whose baseline HIV-1 RNA was
5.30 log10 copies/mL and whose baseline (pre-therapy) population genotype was wild-type and who at failure had an HIV-1 RNA of
2.87 log10 copies/mL and a population genotype of K65RþS68N/SþY115F/YþV118I. Clonal analysis detected distinct viral species, and some of
these clonal variants contained different mutational patterns at baseline and at VF from those observed by population sequencing. Phylogenetic
trees were constructed by using the neighbour-joining method and out-grouped with HXB2RT (HXB2 reverse transcriptase reference sequence). The
scale indicates the relative phylogenetic distance. WT, wild-type.
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JACThe rapid selection of multiple HIV mutations in some of these
subjectsmaybedueinparttothehighbaselineviraemiaobserved
forthosesubjectswithVFinthisstudy,astheopportunityforselec-
tion of mutations with a replication advantage under drug selec-
tion pressure would have been increased as compared with
subjects with lower baseline viral loads. Although this was an ART-
naivestudypopulation,forsevenoftheVFsubjectslow-abundance
viralspeciespossessingpre-existingNRTImutationsweredetected
at baseline. These included mutations considered to be multidrug
resistance-conferring mutations (such as F77L and A62V) that
could have provided a replication advantage under drug pressure
from which more ﬁt mutations might be selected. The presence
of M184V has been previously associated with a lower incidence
of treatment-emergent TAMs independent of time on therapy,
suggesting a direct effect of M184V on reduced selection of
TAMs.
19 By both conventional (PG) and clonal sequencing
methods, virus from four of the VF subjects (including the post-VF
results of Subject 1) selected TAMs but had no detectable M184V
by clonal analysis at their last study visit, and this lack of M184V
selection may have resulted in a more rapid selection of multiple
TAMs. It also cannot be ruled out that the use of zidovudine once
daily rather than twice daily might have contributed to a lowered
genetic barrier towards selection for TAMs.
Limited data from another clinical study by Moyle et al.
20
support the hypothesis that TAMs is the preferred selection
pathway in HIV-1-infected, ART-naive subjects treated with aba-
cavir/lamivudine/zidovudineþtenofovir. In the as-treated analysis,
1/40 subjects treated with twice-daily abacavir/lamivudine/
zidovudineþonce-daily tenofovir experienced VF; virus from this
subject also selected for M184VþTAMs (D67N, K70E, T215Y and
K219E), and the authors noted that this subject had incomplete
regimen adherence.
20 For COL40263, anecdotal communication
from the study sites suggested that incomplete adherence was
also a factor in the majority of VFs, which may suggest that adher-
ence is especially important in ART-naive subjects with high-level
viraemia who initiate therapy, and may be more critical for sub-
jects residing in geographic areas where the incidence of trans-
mitted drug resistance mutations is known to be elevated.
Sturmer et al.
21 have also extensively reviewed ﬁndings from
a number of primarily single-arm studies in ART-experienced
subjects who later received abacavir/lamivudine/zidovudineþ
tenofovir. In their cross-study comparison, they concluded that
this regimen was an efﬁcient treatment strategy in moderately
pre-treated patients and that virological success was observed
for this regimen in the presence of the M184V mutation and
low numbers of TAMs, although the presence of at least two
TAMs, especially when the T215Y/F mutation was present, or
the L210W mutation alone was a predictor of VF. The role of
pre-existing K65R as a predictor of VF for a later treatment
regimen with quadruple abacavir/lamivudine/zidovudineþ
tenofovir therapy was unable to be clearly addressed in the
review of Sturmer et al.
21 due to low sample numbers. Virological
response and mutational proﬁle at failure results were also sum-
marized by these authors for naive and pre-treated patients who
received lamivudine/zidovudineþtenofovir therapy in several
studies; the majority of these subjects achieved virological sup-
pression on therapy. For those subjects who met VF criteria
and had detectable resistance mutations at failure,
TAMsþM184V was the predominant pattern, although a low
incidence of K65R was detected.
K65R was also observed at low incidence (2/14 subjects) at VF
in COL40263. Interestingly,one of the two subjects whose HIVdid
select for K65R may have been predisposed to selection of the
K65R mutation by the presence of the K70E mutation, as low-
abundance clones with this mutation were detected at baseline.
K70E has been shown in macaques to precede selection for
K65R when treated with tenofovir and also to precede selection
for K65R in patients when tenofovir, abacavir and lamivudine
are co-administered.
22,23 While K70E and K65R are both selected
by tenofovir, they appear to be structurally incompatible, and,
when both are detected byPG afterinvivo treatment with tenofo-
vir, theyoccuron separate viral genomes. The K70E mutationalso
produces slightly less tenofovir resistance, suggesting that under
tenofovir selection pressure virus with K65R will have a growth
advantage.
24 Since tenofovir was administered separately from
theco-formulatedabacavir/lamivudine/zidovudine,itisalsoposs-
ible that K65R could have emerged through partial adherence to
the drug regimen, or that use of zidovudine once daily rather
than twice daily was not sufﬁcient in some patients to modulate
selection in those patients experiencing VF towards a TAM
pathway.
No clone from any of the subjects with VF contained both
K65R and T215F or Y mutations. This agrees with the ﬁndings
of Parikh et al.,
3 who have suggested that there is no net evol-
utionary beneﬁt for the virus to simultaneously select both
TAMs and K65R. This antagonism may be a pan-HIV phenom-
enon, as a similar counterselection for K65R by mutations at
T215 in subjects infected with HIV-2 was recently reported.
25
Furthermore, the HIV-1 from Subject 1, which had selected
K65R mutations at VF, continued to evolve under drug selection
pressure and, at a post-VF timepoint, two distinct clonal popu-
lations emerged, those containing K65R and another that con-
tained TAMs. Taken as a whole, the data from this study
suggest that TAM selection is a preferred resistance route,
rather than K65R, when zidovudine is combined with abacavir,
lamivudine and tenofovir and is consistent with PG results from
in vivo studies in HIV-1-infected antiviral-naive or -experienced
subjects treated with this quadruple regimen in which TAMs
were more likely to be detected than K65R.
20,21 The clonal
data from this study also suggest that for ART-naive subjects
receiving this regimen, the pathway may also be biased
towards selection via the 215F pathway, as this regimen was
more common than T215Y. By utilizing the more sensitive
technique of CG, it was possible to detect low-frequency
drug-resistant variants in these ART-naive subjects at baseline,
and the presence of these baseline variants in this cohort of ART-
naive subjects with high baseline viraemia may have helped drive
resistance down speciﬁc pathways. This suggests that for a min-
ority of patients ultrasensitive techniques may be useful in detec-
tion of variants that can impact response on therapy and should
alter choice of second-line regimens.
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